摘要
目的:探讨吲哚布芬联合替格瑞洛对老年冠心病患者经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后的应用效果。方法:选择2018年11月-2019年3月在兴国县人民医院住院并行PCI术的患者60例,按照随机数字表法分为对照组和治疗组,每组30例。对照组PCI术后应用阿司匹林联合替格瑞洛治疗,治疗组采用吲哚布芬联合替格瑞洛治疗。比较两组临床疗效、血小板聚集率、血小板参数及肝肾功能指标、不良心血管事件、出血事件与不良反应发生情况。结果:治疗组临床总有效率93.33%,高于对照组73.33%,差异有统计学意义(P<0.05)。用药后两组血小板聚集率均明显降低,且治疗组降低更明显(P<0.05)。两组血小板四项指标与肝肾功能指标治疗前后比较,差异均无统计学意义(P>0.05)。治疗组不良心血管事件发生情况均低于对照组(P<0.05);两组出血事件及不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:对PCI术后的老年冠心病患者应用吲哚布芬联合替格瑞洛的效果明显,可降低不良心血管事件的发生率,有助于患者术后康复。
Objective:To investigate the clinical effect of Indobufen combined with Ticagrelor on elderly patients with coronary heart disease after percutaneous coronary intervention(PCI).Method:A total of 60 patients hospitalized with PCI surgery from November 2018 to March 2019 in Xingguo People’s Hospital were selected,they were divided into control group and treatment group according to the random number table method,30 patients in each group.The control group was treated with Aspirin combined with Ticagrelor after PCI,while the treatment group was treated with Indolbufen combined with Ticagrelor.Clinical efficacy,platelet aggregation rate,platelet parameters,indicators of liver and kidney function,adverse cardiovascular events,bleeding events and adverse reactions were compared between the two groups.Result:The total clinical effective rate of the treatment group was 93.33%,higher than 73.33%of the control group,the difference was statistically significant(P<0.05).After treatment,the platelet aggregation rate of both groups was significantly reduced,and the treatment group was more significantly reduced(P<0.05);there were no statistically significant differences between the four platelet indexes,liver and kidney function indexes of the two groups before and after treatment(P>0.05).The incidence of adverse cardiovascular events in the treatment group was lower than that of the control group(P<0.05).There were no statistically significant difference in the incidence of bleeding events and adverse reactions between the two groups(P>0.05).Conclusion:Indolibufen combined with Ticagrelor has obvious effect on elderly coronary heart disease patients after PCI,which can reduce the incidence of adverse cardiovascular events and contribute to postoperative rehabilitation of patients.
作者
曾繁枋
邱倩
方厚民
李彬
ZENG Fanfang;QIU Qian;FANG Houmin;LI Bin(Xingguo People’s Hospital,Xingguo 342400,China;不详)
出处
《中国医学创新》
CAS
2020年第29期144-147,共4页
Medical Innovation of China
基金
江西省卫生健康委科技计划项目(20204715)。
关键词
吲哚布芬
替格瑞洛
老年冠心病
经皮冠状动脉介入治疗
Indobufen
Ticagrelor
Elderly coronary heart disease
Percutaneous coronary intervention
作者简介
通信作者:曾繁枋。
